Top

Published in:

01-03-2018 | Review Article

Role of RPLND and Metastasectomy in the Management of Oligometastatic Renal Cell Carcinoma

Authors: H. Nagaraja, N. Srivatsa, S. Hemalatha, S. Shweta, S. K. Raghunath

Published in: Indian Journal of Surgical Oncology | Issue 1/2018

Abstract

Although lymphadenectomy is currently accepted as most accurate and reliable staging procedure for lymph node metastases, its therapeutic benefit in renal cell carcinoma (RCC) still remains controversial. Although the new, targeted therapy paradigms have changed the treatment of patients with advanced RCC and offer prolonged survival, cure is extremely uncommon in the absence of surgical resections. In this paper, the current role of metastasectomy is reviewed. Review the available literature concerning the role of retroperitoneal lymph node dissection and metastasectomy in outcome of oligometastatic RCC. A PubMed search was conducted to identify original articles, review articles, and editorials addressing the role of retroperitoneal lymph node dissection and metastasectomy in outcome of oligometastatic RCC. Keywords included renal tumors, renal cell cancer, kidney cancer, lymphadenectomy, metastasectomy, and oligometastases. While there is no randomized study available, recent large observational studies have better defined the prognosis of patients with metastatic RCC with or without metastasectomy and RPLND. To date, the available evidence suggests that RPLND and metastasectomy may be beneficial when technically feasible in patients with locally advanced (unfavorable clinical and pathologic characteristics) and oligometastatic disease. A proportion of patients will achieve long-term survival with aggressive surgical resection.

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8 CrossRefPubMed

Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8(6):378–382. https://doi.org/10.1038/nrclinonc.2011.44 CrossRefPubMed

Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571–573CrossRef

Chow WH, Devesa SS, Warren JL (1999) The rising incidence of renal cell carcinoma in the United States of America. JAMA 282:1629–1312

Motzer RJ, Bander NH, Nanus DM (1996) Renal cell carcinoma. N. Engl. J. Med 335(12):865–875CrossRefPubMed

Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. https://doi.org/10.1093/annonc/mdr362 CrossRefPubMed

Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastasis to the lung. J Urol 42(3):269–276. https://doi.org/10.1016/S0022-5347(17)71516-9 CrossRef

Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H (2002) Long term results after pulmonary resection of renal cell carcinoma metastasis. Ann Thorac Surg 73(4):1082–1087. https://doi.org/10.1016/S0003-4975(01)03602-5 CrossRefPubMed

Friedel G, Hürtgen M, Penzenstadler M, Kyriss T, Toomes H (1999) Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res 19:1593–1596

10.

Pfannschmidt J, Hoffmann H, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74(5):1653–1657. https://doi.org/10.1016/S0003-4975(02)03803-1 CrossRefPubMed

11.

Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallrichs SL, Trastek VF, Pairolero PC (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57(2):339–344. https://doi.org/10.1016/0003-4975(94)90994-6 CrossRefPubMed

12.

Zekri J, Ahmed N, Coleman RE, Hancock BW (2001) The skeletal metastatic complications of renal cell carcinoma. Int. J. Oncol 19(2):379–382PubMed

13.

Jung ST, Ghert MA, Harrelson JM, Scully SP (2003) Treatment of osseous metastasis in patients with renal cell carcinoma. Clin Orthop Relat Res 409:223–231. https://doi.org/10.1097/01.blo.0000059580.08469.3e CrossRef

14.

Alves A, Adam R, Majno P, Delvart V, Azoulay D, Castaong D, Bismuth H (2003) Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol 10(6):705–710. https://doi.org/10.1245/ASO.2003.07.024 CrossRefPubMed

15.

Suppiah R, Shaheen PE, Elson P et al (2006) Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107(8):1793–1800CrossRefPubMed

16.

Ruys AT, Tanis PJ, Iris ND, van Duijvendijk P, Verhoef C, Porte RJ, van Gulik TM (2011) Surgical treatment of renal cell cancer liver metastasis: a population based study. Ann Surg Oncol 18(7):1932–1938. https://doi.org/10.1245/s10434-010-1526-x CrossRefPubMedPubMedCentral

17.

McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK (2014) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65(3):577–584. https://doi.org/10.1016/j.eururo.2013.08.012 CrossRefPubMed

18.

Bennington JL (1973) Proceedings: cancer of the kidney-etiology, epidemiology and pathology. Cancer 32(5):1017–1029. https://doi.org/10.1002/1097-0142(197311)32:5<1017::AID-CNCR2820320501>3.0.CO;2-Z CrossRefPubMed

19.

Ballarin R, Spaggiari M, Cautero N, Deruvo N, Montalti R, Longo C et al (2011) Pancreatic metastasis from renal cell carcinoma: the state of the art. World J Gastroenterol 17(43):4747–4756. https://doi.org/10.3748/wjg.v17.i43.4747 CrossRefPubMedPubMedCentral

20.

Yuasa T, Inoshita N, Saiura A, Yamamoto S, Urakami S, Masuda H, Fujii Y, Fukui I, Ishikawa Y, Yonese J (2015) Clinical outcome of patients with pancreatic metastases from renal cell cancer. BMC Cancer 15(1):46. https://doi.org/10.1186/s12885-015-1050-2 CrossRefPubMedPubMedCentral

21.

Bianchi M, Sun M, Jeldres C (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. https://doi.org/10.1093/annonc/mdr362 CrossRefPubMed

22.

Tsui KH, Shvarts O, Barbaric Z (2000) Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol 163(2):437–441. https://doi.org/10.1016/S0022-5347(05)67895-0 CrossRefPubMed

23.

Kuczyk M, Munch T, Machtens S (2002) The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int 89(6):517–522. https://doi.org/10.1046/j.1464-410X.2002.02671.x CrossRefPubMed

24.

Saitoh H, Nakayama M, Nakamura K, Satoh T (1982) Distant metastasis of renal adenocarcinoma in nephrectomized cases. J Urol 127(6):1092–1095. https://doi.org/10.1016/S0022-5347(17)54243-3 CrossRefPubMed

25.

Mortensen H (1948) Transthoracic nephrectomy. J Urol 60(6):855–858. https://doi.org/10.1016/S0022-5347(17)69315-7 CrossRefPubMed

26.

Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML (2011) Lymph node dissection at the time of radical nephrectomy for high risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 59(1):18–23. Crispen PL

27.

Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101(3):297–301. https://doi.org/10.1016/S0022-5347(17)62331-0 CrossRefPubMed

28.

Parker AE (1935) Studies on the main posterior lymph channels of the abdomen and their connections with the lymphatic’s of the genito-urinary system. Am J Anat 56(3):409–443. https://doi.org/10.1002/aja.1000560305 CrossRef

29.

Herrlinger A, Schrott KM, Schott G, Sigel A (1991) What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 146(5):1224–1227. https://doi.org/10.1016/S0022-5347(17)38052-7 CrossRefPubMed

30.

Whitson JM, Harris CR, Reese AC et al (2011) Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastasis. J Urol 185:1615–1620CrossRefPubMed

31.

Delacroix SE Jr, Chapin BF, Chen JJ et al (2011) Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol 186:1236–1241CrossRefPubMed

32.

Blute ML, Leibovich BC, Cheville JC et al A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 172(2):465–469

33.

Terrone C, Guercio S, De Luca S et al The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int 91(1):37–40

34.

Blom JHM, van Poppel H, Marechal JM et al (2009) Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55(1):28–34. https://doi.org/10.1016/j.eururo.2008.09.052 CrossRefPubMed

Title: Role of RPLND and Metastasectomy in the Management of Oligometastatic Renal Cell Carcinoma
Authors: H. Nagaraja
N. Srivatsa
S. Hemalatha
S. Shweta
S. K. Raghunath
Publication date: 01-03-2018
Publisher: Springer India
Published in: Indian Journal of Surgical Oncology / Issue 1/2018
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-018-0722-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of RPLND and Metastasectomy in the Management of Oligometastatic Renal Cell Carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Small-Sized Thyroid Cancers—a Single Institutional Experience in India

Reconstruction of the Major Defects of the Tissue Scalp

From the Desk of the Editor 2018

Papillary Adenocarcinoma in a Gastric Duplication Cyst

Outcome of Treatment for Medullary Thyroid Carcinoma—a Single Centre Experience

Extent of Thyroidectomy in Differentiated Thyroid Cancers—Review of Evidence